Small cell carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
KRAS exon 3 mutation was found in 4 (21%) SCLC patients, and PTEN exon 7 mutation in only 1 (5%) SCLC patient.
|
31209806 |
2019 |
Small cell carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
Treatment with everolimus decreases MCL-1 in colorectal carcinomas and small cell lung cancer (SCLC) cells but not glioblastoma multiforme (GBM) cells with a PTEN mutational background.
|
30201826 |
2019 |
Small cell carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Several mechanisms for this acquired resistance have been identified, including development of an EGFR T790M mutation, MET amplification, hepatocyte growth factor overexpression, loss of phosphatase and tensin homolog expression, epithelial-mesenchymal transition, and transformation to small cell lung cancer.
|
28786540 |
2017 |
Small cell carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Our analysis identified several genes with relatively low mutation frequency, including PTEN, as highly significant (p < 0.001), suggesting these genes may play an important role in the progression of SCLC.
|
29025592 |
2017 |
Small cell carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
Small cell carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
PTEN M264I mutation was identified only in a TKI-refractory lesion with SCLC transformation, while PIK3CA and RB1 mutations were identified only in pre-treatment primary tumour samples.
|
26400668 |
2015 |
Small cell carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
In comparison to the carcinoids, LCNEC/SCLC tumors presented a stronger loss of nuclear and cytosolic PTEN associated with a loss of PTEN and p53.
|
25884169 |
2015 |
Small cell carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In SCLCs with PTEN loss, PF-4989216 also inhibited PI3K signaling but did not induce BCL2-interacting mediator (BIM)-mediated apoptosis nor was there any effect on cell viability or transformation.
|
24240111 |
2014 |
Small cell carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
The ability of PTEN inactivation to accelerate SCLC in a genetic mouse model suggests that targeting the PTEN pathway is a therapeutic option for a subset of human patients with SCLC.
|
24482365 |
2014 |
Small cell carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
In this report, we examined the combined antitumor effect of adenovirus-mediated PTEN (AdVPTEN) gene therapy and DDP chemotherapy on PTEN-null NCI-H446 human SCLC cells in vitro and in vivo in athymic BALB/c nude mice.
|
23470565 |
2013 |
Small cell carcinoma of lung
|
0.500 |
Biomarker
|
disease |
CTD_human |
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer.
|
22941188 |
2012 |
Small cell carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
We investigated whether mutations of PTEN/MMAC1 play an important role in SCLC tumorigenesis.
|
9467947 |
1998 |
Small cell carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
These data indicate that PTEN/MMAC1 mutations contribute to the pathogenesis and neoplastic evolution in SCLC but not in NSCLC.
|
9696041 |
1998 |